Form 4: Moderna Director Noubar Afeyan Acquires Stock Options

Director Noubar Afeyan acquired stock options for 25,512 shares of Moderna, Inc. on April 30, 2025.

Summary

• On April 30, 2025, Noubar Afeyan, a director of Moderna, Inc., acquired stock options for 25,512 shares.
• The exercise price of these options is $28.54.
• The options vest fully on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, contingent upon continued service.
• The options expire on April 30, 2035.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock option grants, with no inherent positive or negative sentiment.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Moderna, MRNA, Noubar Afeyan, stock options, director, Form 4, beneficial ownership, securities